The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance
These two studies suggest a switch in propellant from HFA-134a to HFA-152a is unlikely to induce post-dose bronchoconstriction in asthma or impact lung MCC, and is not accompanied by any safety concerns.
Authors
- Ilaria Pacchetti
- Aida Emirova (ORCID: https://orcid.org/0000-0003-0009-3721)
- Veronica Puviani
- Michela Salvadori
- François Rony
- Dave Singh (ORCID: https://orcid.org/0000-0001-8918-7075)
- Gianluigi Poli (ORCID: https://orcid.org/0000-0002-3758-7664)
- Maria Foti (ORCID: https://orcid.org/0000-0001-5591-8976)
- Mauro Cortellini
- Kusum S. Mathews (ORCID: https://orcid.org/0000-0002-8810-2794)
- Luca Girardello
Institutions
- Manchester University NHS Foundation Trust (GB)
- Medicines Evaluation Unit (GB)
- Chiesi (Italy) (IT)
- Chiesi (France) (FR)
Publication Details
- Journal
- Pulmonary Pharmacology & Therapeutics
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1016/j.pupt.2025.102358
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Chiesi Farmaceutici
- National Institute for Health and Care Research
- Manchester Biomedical Research Centre
- NIHR Imperial Biomedical Research Centre